Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1273.214 COVID-19 vaccine in infants 12 weeks to <6 months
NCT05584202Phase 2Terminated
- Sponsor
- Moderna Inc
- Start
- Sep 2022
- Primary completion
- Nov 2024
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of elasomeran + imelasomeran in coronavirus disease 2019 (COVID-19), sponsored by Moderna Inc. Started Sep 2022; status: terminated.
02
Drugs
elasomeran + imelasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05584202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05584202.